Cytek Biosciences Quarterly Cash Flow Statement
NASDAQ: CTKBIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cytek Biosciences free cash flow
In the quarter ended Jun 30, 2026, Cytek Biosciences generated $1.4 million of operating cash flow and spent $2.2 million on capital expenditures. That left free cash flow of -$849,000, a free-cash-flow margin of -1.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Cytek Biosciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -12.16M | -18.87M | -44.08M | -5.48M | -5.58M | -11.40M | 9.64M | 941.00K | -10.43M | -6.17M | 5.50M | -6.46M |
| Net Income growth (YoY) | — | — | -557.08% | -682.15% | — | — | +75.23% | — | — | — | +48.01% | -497.05% |
| Depreciation & Amortization | 2.01M | 1.86M | 1.90M | 1.92M | 1.89M | 1.88M | 1.85M | 1.85M | 1.81M | 1.70M | 1.63M | 1.77M |
| Stock-Based Compensation | 5.34M | 4.86M | 5.53M | 5.64M | 6.79M | 6.63M | 7.00M | 7.05M | 7.15M | 5.64M | 5.67M | 5.76M |
| Change in Working Capital | 17.83M | 24.85M | 40.79M | -3.11M | 3.33M | 18.19M | 8.79M | 16.90M | 19.80M | 13.41M | 5.00M | -4.37M |
| Operating Cash Flow | 1.37M | -2.74M | -771.00K | -3.90M | 108.00K | -125.00K | 2.00M | 13.22M | 6.20M | 3.96M | 9.51M | -4.24M |
| Capital Expenditures | -2.22M | -2.17M | -1.00M | -657.00K | -1.58M | -849.00K | -894.00K | -1.01M | -1.05M | -567.00K | -1.50M | -1.33M |
| Investing Cash Flow | 7.02M | -27.08M | -1.84M | 18.92M | -16.41M | 9.45M | -63.43M | -15.81M | 2.02M | -5.75M | 29.07M | 43.12M |
| Share Repurchases | 0 | 0 | 34.00K | 29.00K | -4.51M | -10.63M | -7.00M | -11.90M | -2.70M | 0 | -34.60M | -8.43M |
| Debt Repaid | -1.61M | -869.00K | -2.94M | -145.00K | -142.00K | -1.52M | -139.00K | -140.00K | -139.00K | -139.00K | -140.00K | -138.00K |
| Financing Cash Flow | -814.00K | 3.98M | -1.23M | 1.94M | -2.60M | -11.54M | -3.64M | -12.08M | -1.71M | 1.61M | -33.75M | -8.27M |
| Net Change in Cash | 8.18M | -25.19M | -2.43M | 17.81M | -19.83M | -3.45M | -63.56M | -15.62M | 8.78M | 1.51M | 4.00M | 32.09M |
| Free Cash Flow | -849.00K | -4.90M | -1.77M | -4.55M | -1.47M | -974.00K | 1.10M | 12.21M | 5.15M | 3.39M | 8.01M | -5.57M |
This table shows 12 quarterly periods of Cytek Biosciences's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CTKB's reporting calendar. What is a cash flow statement?